# Individualized Pharmacological Approach to Obesity in Patients With Bipolar Disorder

> **NCT07213466** · PHASE4 · RECRUITING · sponsor: **Mayo Clinic** · enrollment: 100 (estimated)

## Conditions studied

- Bipolar I Disorder
- Bipolar II Disorder
- Schizo Affective Disorder
- Obesity
- Weight Loss
- GLP - 1

## Interventions

- **BEHAVIORAL:** Group Therapy Program
- **DRUG:** semaglutide
- **DRUG:** Phentermine-Topiramate
- **DRUG:** naltrexone and bupropion (combination)

## Key facts

- **NCT ID:** NCT07213466
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-19
- **Primary completion:** 2028-02-01
- **Final completion:** 2029-02-01
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2026-03-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07213466

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07213466, "Individualized Pharmacological Approach to Obesity in Patients With Bipolar Disorder". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07213466. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*